- Home
- VGI vs OKYO Comparison
VGI vs OKYO Comparison
Compare VGI & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | OKYO |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.7M | 71.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VGI | OKYO |
|---|---|---|
| Price | $6.72 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 42.6K | ★ 84.1K |
| Earning Date | 01-01-0001 | 07-20-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.66 | $1.28 |
| 52 Week High | $8.04 | $3.20 |
Technical Indicators
Market Signals| Indicator | VGI | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 25.87 | 42.57 |
| Support Level | N/A | $1.31 |
| Resistance Level | $7.99 | $1.72 |
| Average True Range (ATR) | 0.12 | 0.09 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 16.36 | 37.14 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.